SUSAN COREY: Open Payments
NPI 1144594680 · MILTON, DE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,104 in 42 payments from 12 companies in 2025. Trend: 2023 $1,141 · 2024 $1,058 · 2025 $1,104
Food & beverage: $954Honoraria: $150
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 17 | $417 |
| Vanda Pharmaceuticals Inc. | 6 | $211 |
| H2-Pharma, LLC | 1 | $150 |
| Axsome Therapeutics, Inc. | 5 | $98 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $56 |
| Teva Pharmaceuticals USA, Inc. | 2 | $36 |
| ABBVIE INC. | 2 | $34 |
| Collegium Pharmaceutical, Inc. | 2 | $33 |
| ACADIA Pharmaceuticals Inc | 1 | $20 |
| E.R. Squibb & Sons, L.L.C. | 1 | $18 |
Products named: INGREZZA, FANAPT, Auvelity, TRINTELLIX, AUSTEDO XR, VRAYLAR, Jornay PM, NUPLAZID.
Industry payments across DE — which companies pay providers there.
